Viatris Inc. (VTRS) Stock: Price, Forecast & Analyst Target
Viatris Inc. (VTRS) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $19.88 (-1.97%), as of the Nov 19, 2026 trading session; market cap $22.8B.
Educational signal · not a buy or sell recommendation · How to read this
Viatris Inc. · VTRS · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Viatris sells branded medicines, generics, complex generics, biosimilars and active pharmaceutical ingredients through pharmacy, wholesale, government and institutional channels worldwide. The defining question is whether broad commercial reach and durable cash generation can overcome a prolonged revenue contraction, recurring accounting losses and debt far above cash while Nashik manufacturing remediation pressures sales.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Viatris (VTRS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $3.75B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 7 of the last 8 reports
- Altman Z 1.20 · Piotroski F 7
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $19.88 | |
| Change on the day | -1.97% | |
| 52-week range | $10.15–$21.20 | |
| Market capitalisation | $22.8B | — |
| Shares traded on the day | 9.09M | |
| Beta (volatility vs the S&P 500) | 0.87 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Viatris (VTRS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Viatris (VTRS), and what does it report?
Short answer · as of
Viatris is not simply a generic-drug manufacturer. Brands provide the larger revenue pool, generics remain substantial, and the portfolio extends into biosimilars and pharmaceutical ingredients sold through a wide distribution network.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue reporting separates Brands from Generics, while the operating structure spans Developed Markets, Greater China, JANZ and Emerging Markets. Reported sales therefore combine mature named medicines and substitutable products across distinct channels and geographies, rather than measuring demand for a concentrated pipeline.
What do the latest results show for Viatris (VTRS)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $3.75B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Latest quarterly revenue advanced from the preceding period and cleared consensus, while gross profit expanded and operating income turned slightly positive. Net income nevertheless returned to a loss, showing that better commercial and gross-profit performance did not fully reach the bottom line. The annual record remains harsher: revenue has declined successively, and the latest annual loss deepened sharply.
Management expects intermittent disruption and remediation at the Nashik facility to weigh on later-year revenue following a fire and regulatory inspection. Management says that pressure is incorporated into guidance; the next results must establish whether operating performance remains consistent with that assertion.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $3.75B | -$325M | -$0.28 (diluted) |
| Q2 FY2026 | $3.76B | -$119M | -$0.10 (diluted) |
| Q1 FY2026 | $3.52B | $176M | $0.15 (diluted) |
| Q4 FY2025 | $3.70B | -$340M | -$0.30 (diluted) |
What are the financial strengths and risks for Viatris (VTRS)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Operating cash flow remained positive throughout the quarterly record and exceeded capital spending in every reported period, making cash generation materially stronger than the net-income pattern. The trailing cash-flow yield is positive, and the dividend per share has remained unchanged across recent distributions.
Debt greatly exceeds cash and short-term investments. Cash also fell sharply from the preceding period and finished below the opening level of the displayed history, while trailing operating and net margins remained negative. A manufacturing setback that weakens sales or cash conversion would therefore meet a balance sheet with limited cash coverage of debt.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.20 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-4.2%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Viatris (VTRS)?
Short answer · as of
Current published price targets run low $14.00 · high $26.00 · consensus $21.13 · median $21.00 against a quoted price of $19.88 (as of Nov 19, 2026).
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Nashik is the immediate operating checkpoint. Revenue will indicate whether disruption and remediation remain contained within guidance, while gross profit and operating income will show whether the wider portfolio can absorb the pressure without another deterioration in reported profitability.
Cash flow after capital spending, the cash balance and debt deserve equal attention. Forecasts embed rising revenue and earnings across the outlook horizon, so stabilization in the annual revenue pattern and recurring positive net income would offer stronger confirmation than consensus beats that coexist with accounting losses.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Viatris compare with its peers?
Short answer
Viatris's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Viatris differs from a pure generic manufacturer because Brands form the larger reported revenue pool. It also differs from a concentrated drug developer: revenue is spread across established branded medicines, generics, complex formulations, biosimilars and pharmaceutical ingredients distributed through commercial and public healthcare channels.
That breadth reduces dependence on any particular product category, but it creates a different execution burden. Manufacturing continuity, regulatory remediation and portfolio performance across multiple geographies matter alongside research spending, making Nashik an economically relevant test rather than an isolated plant issue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $28.35 Nov 19, 2026 | $5.89B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $38.54 Nov 19, 2026 | $45.0B | 57 5-pillar Nov 18, 2026 | |
| Viatris (VTRS) — this page | $19.88 | $22.8B | 35 |
| $26.70 Nov 18, 2026 | $13.4B | 35 5-pillar Nov 18, 2026 | |
| $199.33 Nov 19, 2026 | $80.7B | 31 5-pillar Nov 18, 2026 | |
| $8.73 Nov 18, 2026 | $3.27B | 30 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $14.00 – $26.00
- Consensus target
- $21.13
- Median target
- $21.00
Consensus record · Captured .
Measured against a quoted price of $19.88 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 11
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 1
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VTRS in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.17% | $38.13M | Added +26.7% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Viatris (VTRS)?
What Investors Ask About Viatris (VTRS) — Healthcare
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How much of Viatris comes from Brands rather than Generics?
Brands are the larger reported revenue pool, although Generics still contribute a substantial share. Viatris should therefore be read as a mixed pharmaceutical portfolio rather than a pure generic supplier.
Why does the Nashik facility matter to Viatris?
Management expects intermittent disruption and remediation at Nashik to affect revenue after a fire and regulatory inspection. The facility matters because manufacturing continuity can constrain sales even when demand across the broader portfolio holds.
Why is Viatris cash-generative despite reporting losses?
Quarterly operating cash flow has stayed positive and above capital spending even while net income has frequently been negative. The divergence means accounting profitability alone does not describe the cash produced by the current portfolio.
What would confirm that Viatris is stabilizing after its revenue contraction?
Sustained revenue improvement, recurring positive operating and net income, and cash generation that preserves liquidity against debt would provide coherent confirmation. Continued estimate beats without durable profitability would leave the underlying question unresolved.
What is the VTRS stock price today?
The last price recorded for Viatris Inc. (VTRS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the VTRS price target?
The analyst consensus price target for Viatris Inc. (VTRS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold VTRS
Funds in our ETF coverage that list VTRS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Davis Select U.S. Equity ETF (DUSA) | 5.76% | |
| SPDV ETF | 2.05% |